- Conditions
- Ischemic Cardiomyopathy, Non-ischemic Cardiomyopathy, Heart Failure, Cardiomyopathies
- Interventions
- AAV1/SERCA2a (MYDICAR), Placebo
- Genetic
- Lead sponsor
- Celladon Corporation
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 409–432
of 10,845
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Solid Tumor
- Interventions
- XTX301
- Drug
- Lead sponsor
- Xilio Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 12
- States / cities
- Sacramento, California • New Haven, Connecticut • Saint Louis Park, Minnesota + 9 more
- Conditions
- Lymphocytic Leukemia, Chronic
- Interventions
- Obinutuzumab, Venetoclax
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 7
- States / cities
- La Jolla, California • Denver, Colorado • New York, New York + 4 more
- Conditions
- Critical Limb Ischemia, Peripheral Arterial Disease, Peripheral Vascular Disease
- Interventions
- Bone marrow concentration device, Placebo procedure (sham)
- Device · Procedure
- Lead sponsor
- Zimmer Biomet
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2020
- U.S. locations
- 25
- States / cities
- Little Rock, Arkansas • Sacramento, California • Miami, Florida + 20 more
- Conditions
- Scoliosis Patients
- Interventions
- Near infrared spectroscopy (NIRS)
- Device
- Lead sponsor
- Joseph D. Tobias
- Other
- Eligibility
- 10 Years to 21 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Non-Small Cell Lung Cancer, Anemia, Cancer, Lung Cancer
- Interventions
- Darbepoetin alfa, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,549 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 277
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Anchorage, Alaska + 243 more
- Conditions
- Preterm Birth
- Interventions
- Docosahexaenoic acid - 800mg/day, Docosahexaenoic acid - 200mg/day, Placebo
- Drug · Other
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 3
- States / cities
- Kansas City, Kansas • Cincinnati, Ohio • Columbus, Ohio
- Conditions
- Cystic Fibrosis (CF)
- Interventions
- MP-376, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 39
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more
- Conditions
- Epilepsy, Epilepsy, Partial
- Interventions
- LAMICTAL extended-release
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 70
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Northport, Alabama + 60 more
- Conditions
- Non Small Cell Lung Cancer ALK Positive or ROS1 Positive
- Interventions
- Lorlatinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 49
- States / cities
- Sedona, Arizona • Huntington Beach, California • Irvine, California + 30 more
- Conditions
- Fibromyalgia
- Interventions
- Pregabalin
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 428 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 93
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 78 more
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
- Interventions
- Cisplatin, CT, Docetaxel, FDG, FLT, PET/CT, Surgery
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 19 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Columbus, Ohio
- Conditions
- Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- GSP304 (tiotropium bromide) Inhalation Solution, GSP304 Placebo Inhalation Solution, Spiriva® Respimat® inhalation spray
- Drug
- Lead sponsor
- Glenmark Specialty S.A.
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 25
- States / cities
- Andalusia, Alabama • Phoenix, Arizona • Tempe, Arizona + 18 more
- Conditions
- Postoperative Atrial Fibrillation
- Interventions
- Amiodarone, DC-cardioversion, Rate Control
- Drug · Procedure
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 523 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 13 more
- Conditions
- Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain
- Interventions
- LY3016859 ISA, LY3556050 ISA, LY3526318 ISA, LY3857210 ISA, Placebo Oral, Placebo, LY4065967 ISA
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 52 more
- Conditions
- Oxidative Stress
- Interventions
- Exposure to nitrous oxide or other volatile anesthetics
- Other
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Cardiothoracic Surgery, Vascular Surgery
- Interventions
- Placebo, ABT-719
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 20
- States / cities
- Gainesville, Florida • Jacksonville, Florida • Tampa, Florida + 16 more
- Conditions
- Breast Cancer, Colorectal Cancer
- Interventions
- Telephone-Based exercise intervention
- Behavioral
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2026
- U.S. locations
- 9
- States / cities
- La Jolla, California • San Francisco, California • Boston, Massachusetts + 6 more
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Positive, Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma
- Interventions
- Brentuximab Vedotin, Crizotinib, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Methotrexate
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2024
- U.S. locations
- 154
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 117 more
- Conditions
- Heart Failure, Respiratory Insufficiency, Stroke Acute, Infectious Diseases, Rheumatic Diseases
- Interventions
- Rivaroxaban, 10 mg, Rivaroxaban, 7.5 mg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 12,024 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 135
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 132 more
- Conditions
- Epilepsy
- Interventions
- Education microlearning sessions, Automated digital reminders, Problem-solving mHealth module, Individualized Adherence Feedback Report
- Behavioral
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 2 Years to 12 Years
- Enrollment
- 268 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 4
- States / cities
- Orange, California • Cincinnati, Ohio • Columbus, Ohio + 1 more
- Conditions
- Autistic Disorder, Enuresis
- Interventions
- Moisture Pager Intervention for Toilet Training, Standard of Care
- Behavioral
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 3 Years to 10 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2018
- U.S. locations
- 3
- States / cities
- Rochester, New York • Columbus, Ohio • Nashville, Tennessee
- Conditions
- Endometriosis
- Interventions
- Leuprolide Oral Tablet - 120 mg - QD- Treatment A, Leuprolide Oral Tablet - 80 mg - QD - Treatment B, Leuprolide Oral Tablet - 60 mg - QD - Treatment C, Leuprolide Oral Tablet - 60 mg - BID - Treatment D, Leuprolide Oral Tablet - 40 mg - BID - Treatment E
- Drug
- Lead sponsor
- Enteris BioPharma Inc.
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 4
- States / cities
- Sarasota, Florida • Columbus, Ohio • Norfolk, Virginia + 1 more
- Conditions
- Candidiasis, Oral, HIV Infections
- Interventions
- Chlorhexidine gluconate
- Drug
- Lead sponsor
- Procter and Gamble
- Industry
- Eligibility
- 13 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 5
- States / cities
- Los Angeles, California • San Francisco, California • Columbus, Ohio + 1 more